Kurisu Tada

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Critical Roles of TRAF2 and TRAF5 in Tumor Necrosis Factor-induced NF-κB Activation and Protection from Cell Death

Kurisu Tada, Tatsuma Okazaki, Sachiko Komazawa‐Sakon et al. · Journal of Biological Chemistry · 2001 · 305 citations · Full text

Tnf-induced Nf-kappab Activation, Apoptosis, Immunology +17

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Targeted disruption of<i>Traf5</i>gene causes defects in CD40- and CD27-mediated lymphocyte activation

Hiroyasu Nakano, Sachiko Komazawa‐Sakon, Haruhiko Koseki et al. · Proceedings of the National Academy of Sciences · 1999 · 184 citations · Full text

Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody–positive inflammatory myositis

Yoshiyuki Abe, Masakazu Matsushita, Kurisu Tada et al. · Lara D. Veeken · 2017 · 108 citations · Full text